IRulya Therapeutics Inc. SEC filings IRLA
IRulya Therapeutics Inc. has 462 filings in SEC EDGAR's recent list, going back to Jan 5, 2016. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 144 | Notice of proposed sale | Nov 5, 2026 | — |
| 144 | Notice of proposed sale | Oct 21, 2026 | — |
| 3 | Initial insider ownership | Oct 19, 2026 | Oct 8, 2026 |
| 3 | Initial insider ownership | Oct 19, 2026 | Oct 8, 2026 |
| 3 | Initial insider ownership | Oct 19, 2026 | Oct 8, 2026 |
| 3 | Initial insider ownership | Oct 19, 2026 | Oct 8, 2026 |
| 3 | Initial insider ownership | Oct 19, 2026 | Oct 8, 2026 |
| 3 | Initial insider ownership | Oct 19, 2026 | Oct 8, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 19, 2026 | Oct 19, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 14, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Oct 14, 2026 | — |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure, Other events
|
Oct 9, 2026 | Oct 7, 2026 |
| S-8 | Employee stock plan registration | Oct 8, 2026 | — |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results
|
Oct 6, 2026 | Oct 6, 2026 |
| DEFA14A | Additional proxy material | Oct 2, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Oct 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Officer or director change
|
Sep 14, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 4, 2026 | Aug 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 27, 2026 | Aug 23, 2026 |
| DEF 14A | Proxy statement | Aug 25, 2026 | Oct 6, 2026 |
| EFFECT | Filing | Aug 24, 2026 | — |
| 8-K |
Current report
Other events
|
Aug 17, 2026 | Aug 17, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Aug 14, 2026 | — |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| 8-K |
Current report
Results of operations
|
Aug 14, 2026 | Aug 14, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2026 | — |
| S-3/A | Filing | Aug 5, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 4, 2026 | — |
| 8-K |
Current report
Officer or director change
|
Jul 31, 2026 | Jul 29, 2026 |
| PRE 14A | Preliminary proxy statement | Jul 31, 2026 | Jul 31, 2026 |
| S-3 | Shelf registration | Jul 31, 2026 | — |
| 8-K/A |
Amended current report
Other events
|
Jul 30, 2026 | May 17, 2026 |
| 8-K/A |
Amended current report
Change to shareholder rights
|
Jun 26, 2026 | Jun 26, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jun 26, 2026 | Jun 26, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 15, 2026 | Jun 11, 2026 |
| 4 | Insider transaction | Jun 11, 2026 | May 18, 2026 |
| 3 | Initial insider ownership | Jun 11, 2026 | May 18, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 11, 2026 | Jun 11, 2026 |
| D | Filing | Jun 11, 2026 | — |
| D | Filing | Jun 11, 2026 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Jun 10, 2026 | — |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 20, 2026 |
| 8-K/A |
Amended current report
Regulation FD disclosure
|
May 18, 2026 | May 17, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, Unregistered share sale, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
May 18, 2026 | May 17, 2026 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | May 15, 2026 | — |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Other events
|
Apr 28, 2026 | Apr 27, 2026 |
| ARS | Annual report to shareholders | Apr 27, 2026 | Dec 31, 2025 |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Jun 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 22, 2026 | Apr 22, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 17, 2026 | Jun 11, 2026 |
| S-8 | Employee stock plan registration | Apr 17, 2026 | — |
| 10-K | Annual report | Apr 10, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Apr 9, 2026 | Apr 9, 2026 |
| NT 10-K | Filing | Apr 1, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Agreement ended, Regulation FD disclosure
|
Mar 30, 2026 | Mar 27, 2026 |
| 8-K |
Current report
Listing notice
|
Mar 20, 2026 | Mar 16, 2026 |
| SCHEDULE 13G | Ownership over 5% (passive) | Mar 5, 2026 | — |
| 8-K |
Current report
Results of operations, Other events
|
Feb 12, 2026 | Feb 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Feb 2, 2026 | Jan 30, 2026 |
| 8-K |
Current report
Other events
|
Jan 29, 2026 | Jan 29, 2026 |
| 4 | Insider transaction | Jan 23, 2026 | Jan 23, 2026 |
| 4 | Insider transaction | Jan 23, 2026 | Jan 23, 2026 |
| 4 | Insider transaction | Jan 23, 2026 | Jan 23, 2026 |
| 4 | Insider transaction | Jan 21, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 21, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 21, 2026 | Jan 2, 2026 |
| 4 | Insider transaction | Jan 21, 2026 | Jan 2, 2026 |
| 144 | Notice of proposed sale | Dec 29, 2025 | — |
| 4 | Insider transaction | Dec 29, 2025 | Dec 26, 2025 |
| 4 | Insider transaction | Dec 29, 2025 | Oct 23, 2024 |
| 4 | Insider transaction | Dec 12, 2025 | Dec 10, 2025 |
| 4 | Insider transaction | Dec 8, 2025 | Dec 5, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Nov 14, 2025 | — |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Oct 30, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure
|
Oct 17, 2025 | Oct 17, 2025 |
| 424B5 | Prospectus supplement | Oct 17, 2025 | — |
| 8-K |
Current report
Material agreement, New debt
|
Sep 26, 2025 | Sep 25, 2025 |
| SCHEDULE 13G | Ownership over 5% (passive) | Aug 14, 2025 | — |
| 10-Q | Quarterly report | Aug 11, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2025 | Aug 11, 2025 |
| EFFECT | Filing | Aug 5, 2025 | — |
| 424B5 | Prospectus supplement | Aug 5, 2025 | — |
| CORRESP | Letter to the SEC | Aug 1, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 1, 2025 | — |
| S-3 | Shelf registration | Jul 25, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jul 16, 2025 | Jul 16, 2025 |
| D | Filing | Jul 1, 2025 | — |
| 4 | Insider transaction | Jun 23, 2025 | Jun 18, 2025 |
| 4 | Insider transaction | Jun 23, 2025 | Jun 18, 2025 |
| 4 | Insider transaction | Jun 23, 2025 | Jun 18, 2025 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Jun 13, 2025 | Jun 12, 2025 |
| 4 | Insider transaction | Jun 6, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 6, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 6, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 6, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 6, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 6, 2025 | Jun 4, 2025 |
| 4 | Insider transaction | Jun 6, 2025 | Jun 4, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2025 | Jun 4, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Apr 30, 2025 | — |
| ARS | Annual report to shareholders | Apr 23, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 23, 2025 | — |
| DEF 14A | Proxy statement | Apr 23, 2025 | Jun 4, 2025 |
| PRE 14A | Preliminary proxy statement | Apr 9, 2025 | Dec 31, 2024 |
| S-8 | Employee stock plan registration | Mar 24, 2025 | — |
| 424B5 | Prospectus supplement | Mar 24, 2025 | — |
| 10-K | Annual report | Mar 24, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2025 | Mar 24, 2025 |
| SCHEDULE 13G/A | Amended ownership over 5% (passive) | Feb 18, 2025 | — |
| SCHEDULE 13G | Ownership over 5% (passive) | Feb 14, 2025 | — |
| 4 | Insider transaction | Feb 11, 2025 | Jan 28, 2025 |
| 4 | Insider transaction | Feb 11, 2025 | Jan 28, 2025 |
| 4 | Insider transaction | Feb 11, 2025 | Jan 28, 2025 |
| 4 | Insider transaction | Jan 8, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 8, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 8, 2025 | Jan 2, 2025 |
| 4 | Insider transaction | Jan 8, 2025 | Jan 2, 2025 |
| 424B5 | Prospectus supplement | Dec 27, 2024 | — |
| EFFECT | Filing | Dec 26, 2024 | — |
| CORRESP | Letter to the SEC | Dec 23, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2024 | — |
| S-3 | Shelf registration | Dec 18, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Nov 14, 2024 | — |
| 8-K |
Current report
Other events
|
Nov 14, 2024 | Nov 12, 2024 |
| SC 13D | Ownership over 5% (active) | Nov 13, 2024 | — |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 4 | Insider transaction | Sep 3, 2024 | Aug 29, 2024 |
| 4 | Insider transaction | Aug 22, 2024 | Aug 20, 2024 |
| 4 | Insider transaction | Aug 21, 2024 | Aug 19, 2024 |
| 10-Q | Quarterly report | Aug 13, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2024 | Aug 13, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Aug 6, 2024 | — |
| 8-K |
Current report
Listing notice
|
Jun 21, 2024 | Jun 20, 2024 |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| 4 | Insider transaction | Jun 7, 2024 | Jun 5, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 6, 2024 | Jun 5, 2024 |
| 4 | Insider transaction | Jun 5, 2024 | Jun 4, 2024 |
| 10-Q | Quarterly report | May 13, 2024 | Mar 31, 2024 |
| ARS | Annual report to shareholders | Apr 24, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 24, 2024 | — |
| DEF 14A | Proxy statement | Apr 24, 2024 | Jun 5, 2024 |
| PRE 14A | Preliminary proxy statement | Apr 11, 2024 | Jun 5, 2024 |
| S-8 | Employee stock plan registration | Apr 1, 2024 | — |
| 10-K | Annual report | Apr 1, 2024 | Dec 31, 2023 |
| 4 | Insider transaction | Feb 15, 2024 | Feb 15, 2024 |
| 3 | Initial insider ownership | Feb 15, 2024 | Feb 15, 2024 |
| 8-K |
Current report
Officer or director change
|
Feb 15, 2024 | Feb 13, 2024 |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 14, 2024 | — |
| SC 13G | Ownership over 5% (passive) | Feb 12, 2024 | — |
| SC 13G/A | Amended ownership over 5% (passive) | Feb 7, 2024 | — |
| 4 | Insider transaction | Feb 2, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 2, 2024 | Feb 1, 2024 |
| 4 | Insider transaction | Feb 2, 2024 | Feb 1, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 29, 2024 | Jan 23, 2024 |
| 4 | Insider transaction | Jan 17, 2024 | Jan 16, 2024 |
| 8-K/A | Amended current report | Jan 5, 2024 | Oct 20, 2023 |
| 8-K |
Current report
Other events
|
Jan 3, 2024 | Dec 29, 2023 |
| 8-K |
Current report
Agreement ended
|
Dec 22, 2023 | Dec 22, 2023 |
| SC 13G | Ownership over 5% (passive) | Dec 15, 2023 | — |
| 4 | Insider transaction | Dec 14, 2023 | Dec 12, 2023 |
| 8-K |
Current report
Listing notice
|
Dec 8, 2023 | Dec 4, 2023 |
| 4 | Insider transaction | Dec 7, 2023 | Dec 5, 2023 |
| 4 | Insider transaction | Dec 1, 2023 | Nov 29, 2023 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 4 | Insider transaction | Oct 26, 2023 | Oct 24, 2023 |
| 8-K |
Current report
Officer or director change
|
Oct 26, 2023 | Oct 24, 2023 |
| 4 | Insider transaction | Oct 24, 2023 | Oct 23, 2023 |
| 3 | Initial insider ownership | Oct 24, 2023 | Oct 23, 2023 |
| 4 | Insider transaction | Oct 24, 2023 | Oct 23, 2023 |
| 3 | Initial insider ownership | Oct 24, 2023 | Oct 23, 2023 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Officer or director change
|
Oct 23, 2023 | Oct 20, 2023 |
| 4 | Insider transaction | Sep 6, 2023 | Sep 1, 2023 |
| 3 | Initial insider ownership | Sep 6, 2023 | Sep 1, 2023 |
| 8-K |
Current report
Material agreement, New debt, Officer or director change
|
Sep 6, 2023 | Aug 30, 2023 |
| 4 | Insider transaction | Aug 31, 2023 | Aug 30, 2023 |
| 4 | Insider transaction | Aug 17, 2023 | Aug 15, 2023 |
| 4 | Insider transaction | Aug 11, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Aug 10, 2023 | Aug 4, 2023 |
| 4 | Insider transaction | Aug 9, 2023 | Aug 8, 2023 |
| 4 | Insider transaction | Aug 9, 2023 | Aug 8, 2023 |
| 4 | Insider transaction | Aug 9, 2023 | Aug 8, 2023 |
| 10-Q | Quarterly report | Aug 3, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Unregistered share sale, Officer or director change, Regulation FD disclosure, Other events
|
Jul 24, 2023 | Jul 21, 2023 |
| SC 13G | Ownership over 5% (passive) | Jul 17, 2023 | — |
| 4 | Insider transaction | May 26, 2023 | May 24, 2023 |
Showing 200 filings, the most recent 200. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IRLA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Haven, CT
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1662774
- Former names
- Quince Therapeutics, Inc. (until Oct 9, 2026); Cortexyme, Inc. (until Aug 1, 2022)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.